Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07596784 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Primary and study completion dates: Aug 27, 2027 to Aug 17, 2027 · Start date changed from estimate of Jul 30, 2026 to Jul 20, 2026 · Site details revised at 10 of 10 sitesv3 Show 3 more changesShow less
    • Primary and study completion dates: Aug 27, 2027 to Aug 17, 2027
    • Start date changed from estimate of Jul 30, 2026 to Jul 20, 2026
    • Site details revised at 10 of 10 sites
  2. Trial sites expanded: 0 → 10 locationsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
727 trials monitored
See 61 trials at risk
Myasthenia Gravis
187 trials monitored
See 7 trials at risk
The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).
Trial Details
NCT Number NCT07596784
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Generalized Myasthenia Gravis, gMG
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov